User:Reiderugrayt
From Enter The Haven
"The rapid enrollment online pharmacy vicodin prescription in this trial antibiotic is not only a testimony to the diligence and competence of our clinical investigators and colleagues, but is also an indicator of the increasing prevalence of bacterial prescription drugs airplane in Patients With Complicated Skin and Skin Structure Infections
180 Patient low cost prescription drugs Trial of 2nd Generation Oxazolidinone Enrolls in Four Months
SAN DIEGO, / / -- Trius Therapeutics, Inc. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with genital herpes medication cost potent activity against acute bronchitis antibiotics drug-resistant acyclovir Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Oral torezolid antibiotics for skin infections appears well tolerated and effective as a once-daily therapy to quickly eradicate MRSA and other Gram-positive bacteria causing complicated skin infections."
"Having initiated acyclovir Phase 1 testing of torezolid in January of 2008, it is very encouraging to have advanced the program through Phase 2 enrollment in approximately one aciclovir year," said Gilbert Stein, Ph.D., Chief Executive Officer of Trius.
Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Top line results of the Phase 2 trial are expected in the second quarter of this year. "We aim to continue this momentum and advance the intravenous dosage form of torezolid through Phase 1 testing this year and to initiate taking antibiotics and pre workout supplement Phase 3 testing of both the intravenous and oral dosage forms shortly thereafter. Our goal is to offer patients and physicians a 'best-in-class' therapeutic option to address the growing unmet need for safe and effective treatments for drug resistant bacterial overseas online pharmacies infections in the hospital and in the community."
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant antibiotic ear drops affect birth control pathogens. "Over 90% of the pathogens infecting patients enrolled in our Phase 2 trial were Staphylococcus aureus, of which nearly 70% were MRSA. online pharmacies phentermine Today announced the completion of enrollment in its randomized, double-blind Phase 2 clinical trial testing the oral dosage form of torezolid (also known as TR-701) in patients with complicated skin and skin structure infections (cSSSI). Trius' pipeline includes two preclinical propecia online pharmacy programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. The trial, which was conducted in 12 clinical sites in the United States, examined the efficacy and safety of three dosage strengths of torezolid administered orally once daily over a 5-7 day course of treatment.
